The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.
Subjects voluntarily participate in this study and have signed the Informed Consent Form (ICF).
Male or female subjects aged ≥ 18 years and ≤ 70 years
A history of plaque psoriasis for ≥6 months at baseline
Psoriasis Area and Severity Index (PASI) score ≥12
Diagnosed with non-plaque psoriasis.
Subject had laboratory values meeting any of the protocol-specified criteria at Screening.
Presence of clinically serious, progressive, or uncontrolled disease.
Previous history of alcoholism or drug abuse (except for those who have been completely abstinent for more than 6 months before randomization).
Parallel
ICP-332 Tablets
DrugICP-332 will be administered as tablet for 12 weeks
ICP-332 Tablets
DrugICP-332 will be administered as tablet for 12 weeks
ICP-332 Tablets
DrugICP-332 will be administered as tablet for 12 weeks
ICP-332 Placebo Tablets
Other interventionPlacebo will be administered as tablet for 12 weeks
The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) at Week 12
Click on the lead sponsor to view all of their trials.
